WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation-Reference-Cited by-同舟云学术

WEE Family Kinase Inhibitors Combined with Sorafenib Can Selectively Inhibit HCC Cell Proliferation

Published:2024-06-10 Issue: Volume:24 Page:
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Chen Anling¹²,Yin Ke³,Liu Yu⁴,Hu Lei⁵,Cui Qianwen¹⁶,Wan Xiaofeng³,Yang Wulin¹²³

Affiliation:

1. Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China

2. Science Island Branch, Graduate School of University of Science and Technology of China, Hefei, 230031, China

3. Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China

4. School of Life Sciences, Bengbu Medical College, Bengbu, 233000, China

5. School of Preclinical Medicine, Wannan Medical College, Wuhu, 241002, China

6. Science Island Branch, Graduate School of University of Science and Technology of China, Hefei, 230031, China;

Abstract

Background: Sorafenib is currently the first choice for the treatment of patients with advanced hepatocellular carcinoma, but its therapeutic effect is still limited. Objectives: This study aims to examine whether WEE family kinase inhibitors can enhance the anticancer effect of sorafenib. Methods: We analyzed the expression levels of PKMYT1 kinase and WEE1 kinase in HCC, studied the inhibitory effect of PKMYT1 kinase inhibitor RP-6306, WEE1 kinase inhibitor adavosertib combined with sorafenib on the proliferation of HCC cells, and detected the effect of drug combination on CDK1 phosphorylation. Results: We found that PKMYT1 and WEE1 were upregulated in HCC and were detrimental to patient survival. Cell experiments showed that both RP-6306 and adavosertib (1-100 μM) inhibited the proliferation of HCC cell lines in a dose-dependent manner alone, and the combination of the two drugs had a synergistic effect. In HCC cell lines, sorafenib combined with RP-6306 or adavosertib showed a synergistic antiproliferation effect and less toxicity to normal cells. Sorafenib combined with RP-6306 and adavosertib further inhibited the proliferation of HCC cells and caused complete dephosphorylation of CDK1. Conclusion: Taken together, our findings provide experimental evidence for the future use of sorafenib in combination with RP-6306 or adavosertib for the treatment of HCC.

Publisher

Bentham Science Publishers Ltd.